It was reported via journal article: "title : morbidity and functional mid-term outcomes using prolift pelvic floor repair systems." authors: sébastien kozal, md; thomas ripert, md; younes bayoud, md; johan menard, md; ioannis nicolacopoulos, md; laurence bednarzyck, md; frederic staerman, md; stéphane larré, md.Citation: can urol assoc j.2014; 8 (9-10): e605-9.Doi: http://dx.Doi.Org/10.5489/cuaj.2022.The authors assess midterm morbidity and functional outcomes using the gynecare prolift mesh system (ethicon) and identify potential related risk factors.The prolift mesh system was used to treat genital prolapse and was introduced in 2005.Over a 7-year period, the authors retrospectively analyzed a cohort of 112 consecutive patients (age range: 40 to 86 years old; bmi: 15 to 41.5) who underwent the prolift procedure since 2006.All women presenting with pelvic organ prolapse (pop) and treated with the prolift mesh system were included.Reported complications included bladder perforation (n-3) which were immediately repaired transvaginally with favorable outcomes, urinary tract infection (n-2), infection (n-2), chronic pain syndrome (n-2), mesh exposure (n-5) which required surgical resection (n-4) and ablation after a secondary retraction at 45 months post-operatively (n-1), mesh retraction (n-2), pop recurrence (n-9), de novo dyspareunia (n-9), failure of treatment (n-9), and de novo prolapse (n-13).Despite market withdrawal, the prolift mesh system was associated with good midterm anatomic outcomes and few severe complications.The main limit was the impact on sexuality and the occurrence of de novo pop.Based on the results, better outcomes were observed in elderly non-obese women with stage 3 or more pop.
|